Ones To Watch News
Refine Search
Biotechnology
Positive top-line results have been reported from the Phase III PRINCE study evaluating the efficacy and safety of pegcetacoplan in adults with paroxysmal nocturnal hemoglobinuria (PNH) who are treatment naïve. 25 May 2021
Biotechnology
Norwegian natural killer cell specialist Zelluna Immunotherapy has entered into two exclusive license agreements with The University of Texas MD Anderson Cancer Center related to MAGE-A4 and VGLL1 targeting allogeneic “off-the-shelf” TCR-NK cell therapies for the treatment of various solid cancers. 25 May 2021
Biotechnology
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Verastem’s investigational RAF/MEK inhibitor VS-6766, combined with defactinib, its FAK inhibitor, in recurrent low-grade serous ovarian cancer (LGSOC) regardless of KRAS status after one or more prior lines of therapy, including platinum-based chemotherapy. 25 May 2021
Biotechnology
Shares of US biotech NGM Biopharmaceuticals closed down more than 40% at $16.81 yesterday, after it revealed a major disappointment with its aldafermin in the treatment of non-alcoholic steatohepatitis (NASH), joining a string of failures in this therapy area. 25 May 2021
Pharmaceutical
US specialty drug company Xeris Pharmaceuticals has entered into a definitive agreement to acquire Strongbridge Biopharma for stock and contingent value rights (CVRs), aiming to create an innovative leader in endocrinology and rare diseases. 24 May 2021
Pharmaceutical
Encouraging signs from an Alzheimer’s study carried out by Annovis Bio doubled the firm’s share price on Friday. 24 May 2021
Biotechnology
The European Medicines Agency’s Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion following the referral of sotrovimab to the CHMP under Article 5(3) of Regulation 726/2004. 21 May 2021
Biotechnology
Swiss clinical-stage biotech Numab Therapeutics today announced the closing of a 100 million Swiss franc (~$110 million) Series C financing. 20 May 2021
Biotechnology
Launched in February 2019 with $60 million financing, US biotech HiberCell today announced that it has completed a Series B financing round for gross proceeds of $67.4 million. 20 May 2021
Biotechnology
Privately-held Austrian biotech APEIRON Biologics today announced the next development steps for APN01 (alunacedase alfa) for the treatment of COVID-19. 19 May 2021
Biotechnology
Shares of Sarepta Therapeutics rose as much as 12% yesterday, after the US biotech announced positive 12-week expression and safety results from the first 11 participants enrolled in Study SRP-9001-103, an open-label study known as ENDEAVOR, which is being conducted in partnership with Roche). 19 May 2021
Biotechnology
UK breakthrough inflammatory disease and immuno-oncology company Mestag Therapeutics has announced a target discovery, option and license agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. 18 May 2021
Biotechnology
Singapore-based clinical-stage biotech Hummingbird Bioscience today announced the close of its $125 million Series C financing round. 18 May 2021
Biotechnology
Finland-based biotech Faron Pharmaceuticals today revealed that it has signed a sub-license agreement for the rights to US patent US9,376,478, which currently extends to 2033. 14 May 2021
Biotechnology
The European Medicines Agency (EMA) has started a rolling review of data on sotrovimab (previously VIR-7831), an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. 7 May 2021
Biotechnology
Newly-established Swiss biotech MoonLake Immunotherapeutics today announced that full results of a Phase IIb study of its tri-specific nanobody sonelokimab have been published in the prestigious journal The Lancet. 6 May 2021
Biotechnology
Shares in US gene therapy company Avrobio closed 19% lower on Monday. 4 May 2021
Biotechnology
Life-cycle investment firm RTW Investments and Dutch biotech ProQR Therapeutics today announced that Yarrow Biotechnology, a company newly created by RTW, has in-licensed exclusive rights to ProQR’s antisense oligonucleotide (ASO) technology to develop and commercialize potential therapies for an undisclosed non-ophthalmic target. 4 May 2021
Biotechnology
Newly-established Swiss biotech MoonLake Immunotherapeutics has in-licensed the tri-specific nanobody sonelokimab (M1095/ALX 0761) from Germany’s Merck KGaA (MRK: DE). 4 May 2021
Biotechnology
Shares of Sarepta Therapeutics closed up nearly 9% at $77.11 yesterday, after the US rare diseases specialist announced positive results from Part A of the MOMENTUM study (Study 5051-201), a global, Phase II, multi-ascending dose clinical trial of SRP-5051, its next-generation peptide phosphorodiamidate morpholino oligomer (PPMO) treatment for patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. 4 May 2021
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze